PMCF Plan EU MDR: What You Need and How to Create It
One of the new aspects introduced in the European Medical Device Regulation 2017/745 (MDR) is post-market clinical follow-up (PMCF).
While PMCF is well-known in the pharmaceutical world, it is a relatively new concept in the medical device industry.
According to the MDR and the Medical Device Coordination Group (MDCG) guidance MDCG 2020-7, issued in April 2020, post-market clinical follow-up is a continuous process that updates the clinical evaluation and is addressed in the post-market surveillance (PMS) plan of medical devices.
In the post-market surveillance system, post-market clinical follow-up is proactive, while post-market surveillance is reactive.
In other words, during PMCF activities, you must proactively look for new post-market clinical data to update your clinical evaluation and identify potential safety issues with your medical device.
So, how do you start your post-market clinical follow-up activities? With a plan, of course!
The European Commission loves plans.
Post-market clinical follow-up is no different.
Annex XIV, part B of the MDR, addresses post-market clinical follow-up and outlines a set of requirements for developing PMCF plans for medical devices.
Essentially, the PMCF plan is meant to:
It is a part of the medical device post-market surveillance plan, as PMCF falls under post-market surveillance activities. PMCF is a core component of EU MDR post market surveillance — [our guide explains how the full PMS system fits together].
The PMCF plan outlines a strategy for collecting medical device clinical evidence.
Medical device manufacturers should ask themselves these questions before starting their PMCF plan to understand what their best PMCF strategy is:
The findings of PMCF are analyzed and documented in a PMCF evaluation report, which is part of the clinical evaluation report and the technical documentation for your medical device.
The PMCF report includes the same sections as the PMCF plan and documents the plan results.
Post-market clinical follow-up can include a variety of methods for gathering clinical evidence. Fortunately, you don’t need to use all of them.
Instead, you can choose the activities that make sense for you and your medical device.
Remember to justify the choice of activities in your PMCF plan!
Two types of PMCF activities are mentioned in the MDR: General and specific.
General PMCF activities are not enough to adequately demonstrate your device’s clinical performance and safety, although they may provide plenty of information for some devices.
Some data collected through general PMCF activities is also subjective, such as user feedback, which makes the data unreliable to a degree.
While specific PMCF activities provide direct access to raw data, they may be out of reach for many medical device manufacturers.
It is worth noting that the MDR requires medical device manufacturers to use general and specific methods for collecting clinical data.
There needs to be guidance on selecting appropriate post-market clinical follow-up activities, just as there is not much guidance available on providing scientific justifications for the chosen methods.
Each PMCF activity has pros and cons, and its usefulness depends on various factors.
If your device is high-risk, you must provide post-market surveillance reports more frequently, which gives you less time to gather enough clinical data for your first PMCF report.
The time you have available impacts which PMCF activities you can choose.
Low sales can make collecting enough clinical data from observational activities challenging.
The clinical evaluation report essentially serves as a gap analysis for PMCF data – how many gaps you need to bridge will impact your choice of PMCF activities. Reviewing your last clinical evaluation report with PMCF in mind can significantly help you understand which PMCF activities you should be doing.
How you measure your medical device’s performance, as well as what data is required and from where can force you to exclude PMCF activities.
Direct access to customers, end-users, and patients can open the door for PMCF surveys and other data collection activities, especially if you can coordinate collaborative efforts.
Likewise, if your end-users are hidden behind distributors, or you need access to patient data (or need to have consent to process the data), you cannot perform PMCF surveys.
If your medical device always requires control from clinical experts or is interventional, you may be able to collect data from clinicians and other healthcare professionals.
Even if there are registries or data sources in place for medical devices in your field, do you have applicable consent to access and process data from them?
As you can see, choosing PMCF activities requires careful consideration, as one medical device manufacturer’s PMCF activities might not work for another.
Yes, “one man’s treasure, another man’s trash” even applies to post-market clinical follow-up for medical devices. Who would’ve thought?
The most common feedback we see on PMCF from the notified bodies is the promise of PMCF activities that still need to be fulfilled.
Manufacturers mention future studies or surveys and fail to comply with or describe PMCF activities in their PMCF plan that still need to be fully realized.
Our recommendation is to not over-commit your PMCF.
A simple PMCF plan with reasonable justifications and adequate activities is better than a complicated PMCF plan, making promises for the future the manufacturer cannot keep.
You can even work with your notified body on your PMCF strategy to avoid problems.
Most notified bodies are available for negotiation around PMCF activities and proposed study plans.